Table 9.
Main findings of studies reporting Quantra results using the QPlus cartridge.
| First Author (Country) | Design | n | Ward | Controls | Clotting Time (CT, s) | Heparinase Clotting Time (CTH, s) | Clot Time Ratio (CT/CTH) | Clot Stiffness (CS, hPA) | Fibrinogen Contribution to Clot Stiffness (FCS, hPA) | Platelet Contribution to clot Stiffness (PCS, hPA) | Conclusions of the Study | Association with the Occurrence of Thrombotic Events | Definition of Hypercoagulability Assessed by VET According to the Authors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Masi et al. (France) [66] |
Prospective case control study | 11/28 | ICU non-COVID-19 ARDS | Reference range as assessed by the manufacturer | N | N | N | N | ↑ | ↑ | Significant increase in procoagulants leading to a pronounced imbalance between procoagulants and anticoagulants, and a subsequent uncontrolled thrombin generation. No fibrinolysis shutdown | NA | NP |
| 17/28 | ICU COVID-19 ARDS | N | N | N | ↑ 1 | ↑ 2 | ↑ 1 | ||||||
| Ranucci et al. (Italy) [67] |
Prospective observational study | 16 (T0: baseline) | ICU mechanically ventilated | Reference range as assessed by the manufacturer | N 3 | NP | NP | ↑ | ↑ | ↑ | Procoagulant profile with a trend to normalization after an increased thromboprophylaxis | NA | NP |
| 9/16 (T1: 14 days later) | N 4 | ↑ 4 | N 4 |
1p < 0.05 as compared with ICU non-COVID-19 patients; 2 p < 0.001 as compared with ICU non-COVID-19 patients; 3 No difference from baseline value with >0.05; 4 p < 0.05 as compared with baseline value. Abbreviations: ICU: Intensive care unit (adults); ARDS: Acute respiratory distress syndrome; N: Result within the reference range; ↑: Result above the reference range; NP: Not provided; NA: Not assessed.